Product information and disease descriptionProduct descriptionProduct information
Indication
4 evidence topics · 5 sources
Population of the pivotal NATiV3 trial: adults with biopsy-proven noncirrhotic MASH and F2 to F3 fibrosis
Company wording of the target population: MASH with moderate and advanced fibrosis
Indication named in the FDA designations: treatment of MASH
Population expansion planned: MASH with compensated cirrhosis
Proposed labeling
No evidence found.